Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Enbrel therapy allowed more rheumatoid arthritis patients to achieve clinical remission

New results from TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) demonstrated that Enbrel® (etanercept) therapy allowed significantly more rheumatoid arthritis (RA) patients to achieve clinical remission at two years compared to patients treated with methotrexate alone.

11 Jun 2004

High vitamin C intake may protect against rheumatoid arthritis

A high vitamin C intake may protect against the development of painful widespread rheumatoid arthritis indicates research published in the Annals of the Rheumatic Diseases.

10 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Lack of funding and staff in the UK hinders patient care

Doctors across the UK are leading innovative approaches to patient care but are blocked from developing their projects further by lack of funding and staff according to a new publication launched today (3 June) by the BMA.

3 Jun 2004

Patients prescribed medication for long term illness rapidly stop taking their medicines

Many patients prescribed a medicine for a long term condition, such as asthma or heart disease, rapidly stop taking their medicines as prescribed, reveals research in Quality and Safety in Health Care.

1 Jun 2004

Using gene therapy to fight rheumatoid arthritis

Guided by a similar principle, arthritis researchers at the University of Florida and Harvard University hope to use gene therapy to help joint cells pump out a harmless protein that parks in receptor sites, leaving a notorious inflammatory agent “circling the lot” and unable to cause pain, swelling and possible joint damage.

21 May 2004

New treatment for dry eye syndrome (keratoconjunctivitis sicca)

Researchers in the department of ophthalmology at the University of Arizona College of Medicine in Tucson played an important role in the development of Restasis, the first alternative to artificial tears for the treatment of dry eye syndrome.

21 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

Facts about prevalence of arthritis in the U.S.A

Arthritis is the leading cause of physical disability in the United States. Arthritis comprises over 100 different disease and conditions. The most common are osteoarthritis, rheumatoid arthritis, fibromyalgia, and gout.

15 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Study identifies key factor causing low iron and anemia in patients with infections and major inflammatory diseases

UCLA researchers found that a member of the immune system’s defense team stimulates a chain reaction leading to chronic anemia in many patients with infections and major inflammatory diseases.

3 May 2004

Psoriasis medications can treat more than the skin

The National Psoriasis Foundation, Dermatology Nurses Association, Dermatologists and People with Psoriasis have collaborated to offer a new resource to help people with psoriasis cope with the social and emotional impact of psoriasis.

27 Apr 2004

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis (RA). The research, led by a team of ASU psychologists, shows increased pain and inflammation for those dealing with high amounts of stress and depression.

26 Apr 2004

Fish oil reduces heart attack and blood vessel disease

Fish oil can help reduce deaths from heart disease, according to new evidence reports announced today by the Agency for Healthcare Research and Quality.

22 Apr 2004

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

A promising new therapy for rheumatoid arthritis

A promising new therapy for rheumatoid arthritis (RA) developed by researchers at the University of California, San Diego (UCSD) School of Medicine re-educates the body's immune system to prevent an attack against healthy joint tissue.

21 Apr 2004

New research findings about T-cell transport shed light on immune system

New research findings about T-cell transport shed light on how the normal immune system functions and could have implications in fighting autoimmune and inflammatory diseases, say researchers at University of Texas Southwestern Medical Center, Dallas.

20 Apr 2004

Bad hygiene may be good for you

A group of scientists at The Scripps Research Institute have found a connection between poor T cell survival in the body and the development of autoimmunity.

16 Apr 2004

Researchers have developed a new method for finding antigens

Researchers at National Jewish Medical and Research Center have developed a method for finding the molecular targets of the immune system, known as antigens.

13 Apr 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004